Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Aurobindo Pharma receives USFDA approval for Dapagliflozin and Metformin Hydrochloride XR Tablets
Stocks to Watch for April 7: Jubilant FoodWorks, Godrej Consumer, Aurobindo Pharma, IRFC and more
From Godrej Consumer Products Ltd expecting double-digit underlying sales growth in Q4 FY26 to IRFC sanctioning and fully disbursing a ₹1,000 crore term loan to Maharashtra State Power Generation Company Limited, here are the stocks to watch ahead of Tuesday’s trading session.
Aurobindo arm CuraTeQ reports positive Phase 3 results for allergy drug BP11
Aurobindo Pharma unit CuraTeQ reports positive Phase 3 data for Xolair biosimilar BP11 in chronic spontaneous urticaria, plans EMA and FDA filings by end of Q2 2026
Aurobindo Pharma approves Rs 800 crore share buyback. Check record date, other key details
Aurobindo Pharma is launching its first share buyback in two years, offering to repurchase over 54 lakh shares at Rs 1,475 each. This tender offer, open to shareholders as of April 16, represents a significant move for the pharmaceutical giant. The company's stock has shown resilience, gaining ground despite broader market declines.
Aurobindo Pharma approves ₹800 crore share buyback; Check premium, record date and more
This is Aurobindo Pharma's first share buyback in nearly two years. Back in August 2024, the company had announced the repurchase of 51.36 lakh equity shares at a price of ₹1,460 apiece. The drugmaker had spent ₹750 crore for this buyback, which was also carried out via the tender offer route.
Aurobindo Pharma arm receives VAI classification from USFDA for Telangana unit
Aurobindo Pharma's subsidiary, Apitoria Pharma, received a 'Voluntary Action Indicated' (VAI) classification from the USFDA for its Telangana facility after a December 2025 inspection.
USFDA action on Eugia unit II puts Aurobindo Pharma shares in focus
The inspection at Unit II was conducted between November 3 and November 14, during which the regulator issued nine observations.
FDA flags Aurobindo Pharma’s Eugia unit after inspection; issues 9 observations
Aurobindo Pharma announced that the US FDA classified its subsidiary Eugia Pharma's unit-II in Bhiwadi as 'Official Action Indicated' after inspection. No business impact is expected. Shares of the company closed 0.80% up at ₹1,289.80 ahead of the announcement on Tuesday, March 17.
Stocks to buy for short term: From Coal India to Aurobindo Pharma— Jigar Patel of Anand Rathi recommends these 3 shares - Mint
Stocks to buy for short term: From Coal India to Aurobindo Pharma— Jigar Patel of Anand Rathi recommends these 3 sharesMint
Stocks to Watch today: ACME Solar, Gravita India, Kalpataru, Raymond Realty
Stocks to Watch today, March 13: Aurobindo Pharma, Godrej Properties, KPI Green Energy, JK Lakshmi Cement, Max Financial Services, and Nectar Lifesciences are among the top stocks to remain in focus
Coal India among 4 stocks that hit 52-week highs & rallied up to 15% in a month
Despite the BSE Sensex falling 829 points to close at 76,034, four BSE 200 stocks—Aurobindo Pharma, Coal India, ABB India and NTPC—scaled fresh 52-week highs, signalling strong momentum and resilience amid broader market weakness.
Nifty Pharma index hits 52-week high; Ipca, Aurobindo rally up to 4%
In the past one month, the Nifty Pharma index has rallied 4.5 per cent, as against 7.8 per cent decline in the benchmark Nifty 50.